INNOVATE Sold 99% of Its Revenue — Then Reported Its Best Quarter
Q3's 43% top-line jump belonged entirely to DBM Global, which left the building five days after quarter-end. What remains is $238 million of debt, a kidney-diagnostics option, and a Q&A line that stayed silent.
HCHC · Earnings Call · 2026-11-12
A farewell quarter dressed as a growth quarter
INNOVATE's third quarter was, on the surface, the strongest operating print in years: revenue of $495.5 million, “an increase of 42.8% compared to $347.1 million in the prior year period” — Mike Sena, CFO · 2026-11-12, adjusted EBITDA up to $40.5 million from $19.8 million, and a swing from a $9.4 million net loss to $15.8 million of net income, or $1.10 per diluted share. Look one line down and the quarter evaporates. DBM Global — structural steel, industrial maintenance, construction modeling — booked $490.6 million of that $495.5 million. Everything else INNOVATE owns generated $4.9 million. And DBMG is gone: the sale to IES Holdings closed on October 5, five days after the quarter ended. Paul Voigt framed it as a period of exceptional performance at DBM Global that arrived “ahead of the completion of its sale in October” — Paul Voigt, Interim CEO · 2026-11-12. Both things are true. Only one of them recurs. The operating detail was genuinely good, which makes the timing more interesting than the numbers. DBMG's gross margin expanded roughly 170 basis points to 15.3%, segment adjusted EBITDA margin rose about 200 basis points to 8.9%, and adjusted backlog finished at $2.7 billion against $1.8 billion at the end of 2025. That is a business accelerating into its own exit — margins, backlog and mix all improving as the sale papers were being drawn.The bill of sale
The transaction did what years of holding-company arithmetic could not. INNOVATE took in roughly $413 million of cash at closing plus an ownership interest in IES, repaid its corporate credit line, and redeemed $325 million of senior secured notes. Mike Sena, plainly: “our total principal indebtedness is now $238.3 million” — Mike Sena, CFO · 2026-11-12 — down from $583.3 million at quarter-end, a 59% cut in gross debt in a single transaction. Two numbers the call did not reconcile. First, $413 million in, less $325 million of notes, less the ~$20 million of credit line implied by the residual, leaves roughly $68 million unaccounted for — fees, taxes, escrow or retained cash, management did not say. Second, the reported cash line of $4.9 million excludes held-for-sale assets, so the balance sheet investors see next quarter will be a different shape entirely from the one reported today. With no Q&A, neither got a follow-up. What is left is a small operating company inside a large capital structure. Spectrum's $3.7 million of revenue reflects only two months of consolidation; the company now carries 25% of the broadcast business under the equity method, with an option for up to 15% more (a potential 40% stake), 287 operating stations, the largest Class A portfolio in the country, and a free option on a second broadcast auction. Life Sciences fell 61.3% to $1.2 million on weaker R2 unit sales; R2 exited with 116 systems carrying into the fourth quarter worth roughly $1.9 million of future revenue, and Glacial fx production at EIT is finally scaling — 30 systems delivered, about 60 more in production by November 30, against worldwide demand cited at 3.1 million. Then the piece that never appears in segment EBITDA: Pansend, 75% owned, holding up to $900 million of aggregate BeneVir milestones from the 2018 Johnson & Johnson sale, of which management says $500 million would accrue to INNOVATE. As transcribed, the components cited — $250 million of development plus $650 million of commercial milestones — sum to the $900 million aggregate, not the $500 million attributed to INNOVATE. Worth asking about. Nobody did.The MediBeacon question that stopped being asked
The most telling thing in this report is a question that has quietly disappeared. On the March 2025 call — the last one with an analyst on it — Brian Charles of R.W. Pressprich asked directly: “you did mention you've engaged Jefferies to help you explore options on maybe monetizing part or all of that business” — Brian Charles, Analyst · 2025-03-31, referring to MediBeacon, then pressed on the $400 million Huadong valuation. Mike Sena's answer was unambiguous: “we're in discussions with medical device and pharmaceutical companies at this point” — Mike Sena, Chief Financial Officer · 2025-03-31. Eighteen months later the banker, the process and the valuation anchor are all absent from the script. MediBeacon is no longer a sale candidate in the telling; it is a commercialization story. The TGFR kidney-function system secured orders for 600 monitors in China, shipping from Q4 2026 through Q2 2027, won investigational device exemption approval for a third-generation wireless sensor, and management now expects initial big-pharma clinical trial use in 2027. The reimbursement work — CMS engagement, private payer coding — is the real gate, and management is explicit that “conversion timing for new technology can take six to 12 months” — Paul Voigt, Interim CEO · 2026-11-12. Against the wider tape, the themes are recognisable ones: kidney care payment reform is live in the market conversation, and reimbursement pressure is the standard reason new diagnostics take years to convert. INNOVATE's argument is that its coding push is an unlock rather than a headwind. That may be right. But the asset analysts once wanted monetized is precisely the asset still sitting in the portfolio, while the cash-generating business is the one that got sold.Silence, and a tape that already turned
That is now four consecutive quarters without a single analyst question — May 2025, August 2025, November 2025 (“There are currently no questions” — Operator · 2025-11-12), and now. A $288 million market cap carrying $238 million of debt and a portfolio of illiquid private assets is hard to research; the transcript history shows a shareholder base that has largely stopped asking. Which makes the timing of the exit the most interesting part of the story. DBMG's stated demand drivers — computing, artificial intelligence, advanced manufacturing, semiconductor production, energy systems, digital connectivity — are exactly the cluster the market has spent the last month marking down. Over thirty days, AI data centers has fallen about 16% across 57 names and data center capacity about 24%, even as the trailing-year table still shows data center AI among the better performers. INNOVATE sold its operating exposure to that buildout at peak backlog and now holds the exposure passively, through IES equity. Foresight or luck, the consequence is the same. The next print is the first pro forma one — a fraction of this size, with no DBMG to hide behind and a debt load that still roughly equals the equity value. The deleveraging is real. The operating story is not yet.Gentlemen, it appears we have no questions this afternoon.